Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955147060> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2955147060 endingPage "S160" @default.
- W2955147060 startingPage "S160" @default.
- W2955147060 abstract "Limited data exist evaluating patients’ WTP for insulin analogue treatment in countries with mainly out-of-pocket payment markets, such as India. This study investigated WTP for BIAsp 30 in patients with T2D in India. A multicenter, prospective, non-interventional study (data collection: 2017/18) in patients previously treated with biphasic human insulin (BHI) in vials and believed able to pay for BIAsp 30 in a FlexPen® or using a Penfill®. The primary endpoint was the proportion of patients willing to pay for BIAsp 30 after 12 weeks. Secondary endpoints were change from baseline in treatment and device satisfaction, and patient preferences for treatment attributes revealed through a nested discrete choice experiment (DCE) at baseline (defined as a clinical decision to initiate BIAsp 30). DCE results were analyzed by mixed logit models. 54.9% of participants were male (n=277/505); mean participant age was 56.4 years and mean diabetes duration 10.9 years. 63.8% of participants had BMI ≥25 kg/m2 and 48.5% had an annual household income 150,000–340,000 Indian Rupees (INR). After 12 weeks’ treatment, 96.4% of participants were willing and able to pay for BIAsp 30. Mean treatment and device satisfaction significantly improved from baseline (p<0.001). The following mean [95% CI] WTP results are reported in INR. Participants were willing to pay 3576 [2755; 4398] for improved glycemic control, 688 [383; 994] for a device upgrade (syringe to Penfill®), or 327 [95; 560] to avoid major hypoglycemia. Additionally, participants would need to be compensated 44 [56; 32] per minor hypoglycemic event. After 12 weeks, Indian patients with T2D previously treated with BHI were willing to pay for BIAsp 30 in a FlexPen® or Penfill®. Furthermore, switching to BIAsp 30 in a FlexPen® or Penfill® improved treatment and device satisfaction. This study increases prescribers’ understanding of WTP for BIAsp 30 in India." @default.
- W2955147060 created "2019-07-12" @default.
- W2955147060 creator A5000810103 @default.
- W2955147060 creator A5006045490 @default.
- W2955147060 creator A5006825886 @default.
- W2955147060 creator A5024051589 @default.
- W2955147060 creator A5049141965 @default.
- W2955147060 creator A5064120714 @default.
- W2955147060 creator A5077914785 @default.
- W2955147060 date "2019-05-01" @default.
- W2955147060 modified "2023-09-30" @default.
- W2955147060 title "PDB120 UNDERSTANDING PATIENTS' WILLINGNESS TO PAY (WTP) FOR BIPHASIC INSULIN ASPART 30/70 (BIASP30) IN A FLEXPEN® DEVICE OR USING A PENFILL® FOR TYPE 2 DIABETES (T2D) TREATMENT IN AN OUT-OF-POCKET PAYMENTS MARKET" @default.
- W2955147060 doi "https://doi.org/10.1016/j.jval.2019.04.667" @default.
- W2955147060 hasPublicationYear "2019" @default.
- W2955147060 type Work @default.
- W2955147060 sameAs 2955147060 @default.
- W2955147060 citedByCount "0" @default.
- W2955147060 crossrefType "journal-article" @default.
- W2955147060 hasAuthorship W2955147060A5000810103 @default.
- W2955147060 hasAuthorship W2955147060A5006045490 @default.
- W2955147060 hasAuthorship W2955147060A5006825886 @default.
- W2955147060 hasAuthorship W2955147060A5024051589 @default.
- W2955147060 hasAuthorship W2955147060A5049141965 @default.
- W2955147060 hasAuthorship W2955147060A5064120714 @default.
- W2955147060 hasAuthorship W2955147060A5077914785 @default.
- W2955147060 hasBestOaLocation W29551470601 @default.
- W2955147060 hasConcept C126322002 @default.
- W2955147060 hasConcept C144024400 @default.
- W2955147060 hasConcept C149923435 @default.
- W2955147060 hasConcept C151956035 @default.
- W2955147060 hasConcept C162324750 @default.
- W2955147060 hasConcept C175444787 @default.
- W2955147060 hasConcept C2777364431 @default.
- W2955147060 hasConcept C2779306644 @default.
- W2955147060 hasConcept C2779908123 @default.
- W2955147060 hasConcept C2780473172 @default.
- W2955147060 hasConcept C2780668416 @default.
- W2955147060 hasConcept C71924100 @default.
- W2955147060 hasConceptScore W2955147060C126322002 @default.
- W2955147060 hasConceptScore W2955147060C144024400 @default.
- W2955147060 hasConceptScore W2955147060C149923435 @default.
- W2955147060 hasConceptScore W2955147060C151956035 @default.
- W2955147060 hasConceptScore W2955147060C162324750 @default.
- W2955147060 hasConceptScore W2955147060C175444787 @default.
- W2955147060 hasConceptScore W2955147060C2777364431 @default.
- W2955147060 hasConceptScore W2955147060C2779306644 @default.
- W2955147060 hasConceptScore W2955147060C2779908123 @default.
- W2955147060 hasConceptScore W2955147060C2780473172 @default.
- W2955147060 hasConceptScore W2955147060C2780668416 @default.
- W2955147060 hasConceptScore W2955147060C71924100 @default.
- W2955147060 hasLocation W29551470601 @default.
- W2955147060 hasOpenAccess W2955147060 @default.
- W2955147060 hasPrimaryLocation W29551470601 @default.
- W2955147060 hasRelatedWork W1592847003 @default.
- W2955147060 hasRelatedWork W2057434408 @default.
- W2955147060 hasRelatedWork W2068655959 @default.
- W2955147060 hasRelatedWork W2121663374 @default.
- W2955147060 hasRelatedWork W2197938513 @default.
- W2955147060 hasRelatedWork W2292311718 @default.
- W2955147060 hasRelatedWork W2371880537 @default.
- W2955147060 hasRelatedWork W2393240391 @default.
- W2955147060 hasRelatedWork W2416228359 @default.
- W2955147060 hasRelatedWork W2760509590 @default.
- W2955147060 hasVolume "22" @default.
- W2955147060 isParatext "false" @default.
- W2955147060 isRetracted "false" @default.
- W2955147060 magId "2955147060" @default.
- W2955147060 workType "article" @default.